Danna nan idan wannan shine sakin labaran ku!

Marasa lafiyar Ciwon Nono na Farko Zasu Iya Gujewa Chemotherapy

A cikin binciken, matan da suka shude tare da 1 zuwa 3 tabbatacce nodes da Recurrence Score® sakamakon 0 zuwa 25 sun nuna rashin amfani daga chemotherapy bayan tsaka-tsakin shekaru biyar na biyo baya, ma'ana za su iya guje wa mummunan tasirin maganin.

Print Friendly, PDF & Email

Exact Sciences Corp. a yau ta sanar da cewa an buga bayanai daga Rx don Node mai kyau, Endocrine Responsive Breast Cancer, ko RxPONDER, an buga gwajin a cikin The New England Journal of Medicine.i Nazarin, wanda SWOG Cancer Research Network mai zaman kanta ke jagoranta kuma ta dauki nauyin karatun. Cibiyar Ciwon Kankara ta Kasa (NCI), ta sami nasarar bayyana fa'idar chemotherapy a farkon matakin, marasa lafiya masu ciwon nono mai kyau tare da Oncotype DX Recurrence Score® sakamakon 0 zuwa 25. Sakamakon farko daga RxPONDER an bayar da rahoton a 2020 San Antonio Cancer Cancer. Taron Taro (SABCS). Yanzu an tabbatar da sakamakon binciken a cikin wannan ɗaba'ar da aka bita.

Mahimmanci, ba a sami fa'idar chemotherapy ba tare da la'akari da adadin nodes ɗin da abin ya shafa, ƙimar ƙari ko girma. A cikin matan premenopausal tare da nodes masu kyau 1 zuwa 3, an sami fa'idar chemotherapy mai mahimmanci.

Kusan kashi ɗaya bisa uku na marasa lafiya da aka gano tare da mai karɓar mai karɓa na hormone (HR) -tabbatacce, HER2-mara kyau ciwon nono na farko yana da ciwon daji wanda ya yada zuwa ƙwayoyin lymph. Yawancin waɗannan marasa lafiya a halin yanzu suna karɓar chemotherapy ko da yake kusan 85% daga cikinsu suna da Sakamakon Makomai na 0 zuwa 25.iii Bugu da ƙari, kusan biyu cikin uku daga cikin ukun farko na masu ciwon nono suna postmenopausal.iv.

Dangane da sakamakon RxPONDER, National Comprehensive Cancer Network® (NCCN®)v ta sabunta ƙa'idodinta don cutar kansar nono kuma ta gane gwajin Makin Nono na Oncotype DX a matsayin kawai gwajin da za a iya amfani da shi don hasashen fa'idar chemotherapy a farkon nono. marasa lafiya da ciwon daji tare da 1 zuwa 3 tabbatacce axillary lymph nodes, ciki har da micrometastases.vi Gwajin Oncotype DX yanzu shine kawai gwajin da aka rarraba a matsayin "wanda aka fi so" tare da mafi girman matakin shaida don kumburi mara kyau da postmenopausal node-positive (1 zuwa 3 tabbatacce nodes). ) marasa lafiya. Bugu da ƙari, NCCN ta ba da shawarar yin la'akari da gwajin don tantance ƙididdiga a cikin marasa lafiya na premenopausal node-positive wadanda ke takarar neman maganin chemotherapy.

Ɗaya daga cikin manyan gwaje-gwajen asibiti a cikin node-positive, HR-positive, HER2-negative farkon ciwon nono, RxPONDER ya sanya mata fiye da 5,000 tare da ƙananan nodes masu kyau zuwa uku. An gudanar da bincike mai zuwa, bazuwar Mataki na III a wurare 632 a cikin ƙasashe tara - Amurka, Kanada, Mexico, Colombia, Ireland, Faransa, Spain, Koriya ta Kudu da Saudi Arabia. Matan da ke da sakamakon maimaitawa na 0 zuwa 25 an bazu su zuwa jiyya tare da maganin hormone kadai ko chemotherapy tare da maganin hormone. An keɓance marasa lafiya da aka keɓe bisa ga sakamakon Makomai, matsayin menopause da nau'in tiyatar kumburin lymph. Ana yin ƙarin nazari da ƙarin bin diddigin haƙuri ta masu binciken SWOG.

Print Friendly, PDF & Email

Game da marubucin

Linda Hohnholz, editan eTN

Linda Hohnholz tana rubuce-rubuce da gyara labarai tun farkon fara aikinta. Ta yi amfani da wannan sha'awar a wurare kamar su Hawaii Pacific University, Chaminade University, da Hawaii's Discovery Center, da yanzu TravelNewsGroup.

Leave a Comment